Pulmonary hypertension as a result of drug therapy

Clinics in Chest Medicine

Volumn 25, Issue 1, 2004, Pages 123-131

  Higenbottam, Tim ^a,b   Laude, Liz ^a   Emery, Celia ^a   Essener, Mohamed ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMINOREX; AMPHETAMINE; ANOREXIGENIC AGENT; CATECHOLAMINE; CHLORPHENTERMINE; COCAINE; DEXFENFLURAMINE; DEXNORFENFLURAMINE; DIAMORPHINE; DOPAMINE; ENDOTHELIN 1; FENFLURAMINE; NICOTINE; NITRIC OXIDE; NORFENFLURAMINE; PHENTERMINE; RAPESEED OIL; SEROTONIN; TRYPTOPHAN;

BIOLOGY; BLOOD FLOW; CATECHOLAMINE RELEASE; CATECHOLAMINERGIC SYSTEM; CLINICAL TRIAL; DOG; DRUG ABUSE; DRUG ACCUMULATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; EOSINOPHILIA; EOSINOPHILIC MYALGIA SYNDROME; EPIDEMIOLOGICAL DATA; GENOTYPE; HEALTH SURVEY; HEART OUTPUT; HUMAN; LUNG PARENCHYMA; LUNG TOXICITY; METABOLISM; MORBID OBESITY; MYALGIA; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SEROTONINERGIC SYSTEM; SPANISH OIL SYNDROME; SYNDROME; TOXIC OIL SYNDROME; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; DEXFENFLURAMINE; EOSINOPHILIA-MYALGIA SYNDROME; FENFLURAMINE; HUMANS; HYPERTENSION, PULMONARY; IATROGENIC DISEASE; SEROTONIN UPTAKE INHIBITORS;

EID: 1542350028     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00133-3     Document Type: Review

References (101)

1. Schnabel KF, Schulz V, Busch S, et al. Drug-induced primary vascular pulmonary hypertension. Med Welt 1976;27:1300-3.
2. Widgren S. Pulmonary hypertension related to aminorex intake. Histologic ultrastructure and morphometric studies of 37 cases in Switzerland. Curr Top Pathol 1977;64:1-64.
3. Gurtner H. Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter. Bull Eur Physiopathol Res 1979;15:897-923.
4. Gurtner HP. Aminorex and pulmonary hypertension: a review. Cor Vasa 1985;27:160-171.
5. Eddahibi S, Launay JM, Sitbon M, et al. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. Am J Respir Crit Care Med 1998;157:1111-9.
6. Naeije R, Maggiorini M, Delcroix M, et al. Effects of chronic dexfenfluramine treatment on pulmonary haemodynamics in dogs. Am J Respir Crit Care Med 1996;154:1347-50.
7. Lullmann H, Parwaresch MR, Settler M, et al. The effects of anoretic agents on the pulmonary pressure and morphology of rat lungs after chronic administration. Arzneimittelforschung 1972;22(12):2096-9.
8. Mehendale HM. Pulmonary deposition and effects of drugs on pulmonary removal of endogenous substances. Fed Proc 1984;43:2586-91.
9. Dahl AR, Gerde P. Uptake and metabolism of toxicants in the respiratory tract. Environ Health Perspect 1994;102:67-70.
10. Foth H. Role of the lung in accumulation and metabolism of xenobiotic compounds- implications for chemically induced toxicity. Crit Rev Toxicol 1995;25:165-205.
11. 2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-ethylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 1997;121(8):1735-43.
12. Samanin R, Garrattini S. Neurochemical mechanism of anoretic drugs. Pharmacol Toxicol 1993;73(2):63-8.
13. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-8.
14. Hitzig P. Combined dopamine and serotonin agonists: a synergistic approach to alcoholism and other addictive behaviours. Md Med J 1993;42:153-6.
15. Pinder RM, Brogen RN, Sawyer PR, et al. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975;10:241-323.
16. Rowland NE, Richmond RM. Area postrema and the anoretic actions of dexfenfluramine and amylin. Brain Res 1999;27(820):86-91.
17. Douglas JG, Munro JF, Kitchin AH, et al. Pulmonary hypertension and fenfluramine. BMJ 1981;283:881-3.
18. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. BMJ 1986;293:51-2.
19. Pouwels HM, Smeets JL, Cheriex EC, et al. Pulmonary hypertension and fenfluramine. Eur Respir J 1990;3:606-7.
20. McTavish D, Heel RC. Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992;43(5):713-33.
21. Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993;70:537-41.
22. WHO Executive summary. World symposium on pulmonary hypertension, Evian, France; 1998. Available at: http://www.who.int/ncd/cud/pph.html.
23. Loyd JE, Butler MG, Foroud TM, et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995;152:93-7.
24. Langleben D. Familial primary pulmonary hypertension. Chest 1994;105(Suppl):13S-16S.
25. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44.
26. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for pulmonary hypertension. Am J Hum Genet 2001;68:92-102.
27. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular features of pulmonary hypertension in patients with hereditary hemorrhagic telandiectasia. N Engl J Med 2001;345:325-34.
28. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromo-some 2q 31-32. Nat Genet 1997;15:277-80.
29. Morse JH, Jones A, Barst RJ, et al. Genetic mapping of primary pulmonary hypertension: evidence for linkage to chromosome 2 in a large family [abstract]. Circulation 1996;94(Suppl i):1-49.
30. Reeves JT, Noonan JA, Lexington K. Microarteriographic studies of primary pulmonary hypertension. Arch Pathol 1973;95:50-2.
31. Herve P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001;22(3):451-8.
32. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352(9129):719-25.
33. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
34. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
35. Peacock AJ. Primary pulmonary hypertension. Thorax 1999;54(12):1107-18.
36. Stevens T, Rosenberg R, Aird W, et al. NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am J Physiol 2001;281:C1422-33.
37. Burke A, Virmani R. More on cardiac myxomas. N Engl J Med 1996;335(19):1462-3.
38. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.
39. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
40. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with primary pulmonary hypertension. N Engl J Med 1993;328:1732-9.
41. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
42. 2+) channels involved in endothelin-1-induced mitogenic responses in vascular smooth muscle. Eur J Pharmacol 2001;422(1-3):15-21.
43. Olschewski H, Simonneau G, Galie N, et al, Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9.
44. Vizza CD, Rocca GD, Roma AD, et al. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care 2001;5(6):355-61.
45. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903.
46. Hoeper MM, Galie N, Simonneau G, et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165(9):1209-16.
47. Rudarakanchana N, Trembath RC, Morrell NW. New insights into the pathogenesis and treatment of primary pulmonary hypertension. Thorax 2001;56:888-90.
48. Meyrick B. The pathology of pulmonary arterial hypertension. Clin Chest Med 2001;22(3):393-404.
49. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-85.
50. Lee S-D, Shroyer KR, Markham NE, et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-34.
51. Tuder RM, Radisavljevic Z, Shroyer KR, et al. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 1998;158(6):1999-2001.
52. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. BMJ 1986;293:51-2.
53. Abenhaim L, Moride Y, Brenot F, et al, for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
54. Mark EJ, Patalas ED, Chang HT, et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997; 337:602-6.
55. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
56. Williamson DF, Yanovski SZ, Myers MD, et al. Appetite-suppressant drugs and valvular heart disease. N Engl J Med 1999;340:476-80.
57. Rich S, Rubin L, Walker AM, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000;117:870-4.
58. Sole MJ, Drobac M, Schwartz L, et al. The extraction of circulating catecholamines by the lungs in normal man and in patients with pulmonary hypertension. Circulation 1979;60:160-3.
59. Bennett JS, Kolodziej MA. Disorders of platelet function. Dis Mon 1992;28:577-631.
60. McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 1984;74:828-33.
61. Nakonechnicov S, Gabbasov Z, Chazova I, et al. Platelet aggregation in patients with primary pulmonary hypertension. Blood Coagul Fibrinol 1996;7:225-7.
62. Gosney J, Heath D, Smith P, et al. Pulmonary endocrine cells in pulmonary arterial disease. Arch Pathol Lab Med 1989;113:337-41.
63. Celada P, Martin F, Artigas F. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 1994;55:1237-43.
64. Rothman RB, Redmon B, Raatz SK, et al. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 2000;85:913-6.
65. Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999;54:161-8.
66. Herve P, Launay J-M, Scrobohaci M-L, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54.
67. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-50.
68. Fanburg BL, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 1997;272:L795-806.
69. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001;10(6):827-31.
70. Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natiuretic peptide, transforming growth factorbeta and fibroblast growth factor. Cancer 2003;87(7):1609-15.
71. Stahl SM, Levin B. Serotonin depletion by fenfluramine in the carcinoid syndrome. N Engl J Med 1982;18;306(7):429.
72. Rothman RB, Ayestas MA, Dersch CM, et al. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates implications for primary pulmonary hypertension. Circulation 1999;100:869-75.
73. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(Suppl 1):19-26.
74. Seiler KU, Wassermann O. Evidence for an unusual distribution of chlorphentermine in vivo: an autoradiographic study in mice. Naunyn Schmiedebergs Arch Pharmacol 1974;282:113-22.
75. Gross AS, Phillips AC, Rieutord A, et al. The influence of the sparteine/debrisoquine genetic polymorphism on the metabolism of dexfenfluramine. Br J Clin Pharmacol 1996;41:311-7.
76. Guidice JM, Marez D, Sabbagh N, et al. Evidence for CYP2D6 expression in human lung. Biochem Biophys Res Commun 1997;241(1):79-85.
77. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterisation of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
78. Higenbottam TW, Humbert M, Simmoneau G, et al. Subjects deficient for CYP2D6 expression (poor metabolisers) are overrepresented among patients with anorectic associated pulmonary hypertension. Am J Respir Crit Care Med 1999;159(3):A165.
79. Mennini T, Garattini S, Caccia S. Anorectic effect of fenfluramine isomers and metabolites: relationship between brain levels and in vitro potencies on serotonergic mechanisms. Psychopharmacology (Berl) 1985;85(1):111-4.
80. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41.
81. (2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57(1):75-81.
82. MacLean M, Herve P, Eddahibi S, et al. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000;131:161-8.
83. Yakel Jr DL, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J 1995;30(2):398-9.
84. Collazos J, Martinez E, Frenandez A, et al. Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med 1996;90:171-4.
85. Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long term inhalation of "crank" methamphetamine. Chest 1993;104:614-6.
86. Kalivas PW, Duffy P. Effects of daily cocaine and morphine treatment on somato-dendritic and terminal held dopamine release. J Neurochem 1988;50:1498-504.
87. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4- methylenedioxymethamphetamine (MDMA, ecstasy) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003;63(6):1223-39.
88. Parrott AC. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002;71(4):837-44.
89. Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloro-amphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 1992;215:153-60.
90. Garcia-Dorado D, Miller DD, Garcia EJ, et al. An epidemic of pulmonary hypertension after toxic rapeseed oil ingestion in Spain. J Am Coll Cardiol 1983;1:1216-22.
91. Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 2001;23(2):231-47.
92. Gelpi E, de la Paz MP, Terracini B, et al, WHO/CISAT Scientific Committee for the Toxic Oil Syndrome. Centro de Investigacion para el Sindrome del Aceite Toxico. The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge. Environ Health Perspect 2002;110(5):457-64.
93. Kilbourne EM, Rigau-Perez JG, Heath CW, et al. Clinical epidemiology of toxic-oil syndrome: manifestations of a new illness. N Engl J Med 1983;309:1408-14.
94. López-Sendón J, Gomez Sanchez MA, Mestre de Juan MJ, et al. Pulmonary hypertension in the toxic oil syndrome. In: Fishman AP, editor. The pulmonary circulation: normal and abnormal. Philadelphia: University of Pennsylvania Press; 1990. p. 385-95.
95. Ladona MG, Izquierdo-Martinez M, Posada de la Paz MP, et al. Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome. Environ Health Perspect 2001;109(4):369-75.
96. Tazelaar HD, Myers JL, Drage CW, et al. Pulmonary disease associated with L-tryptophan- induced eosinophilic myalgic syndrome. Clinical and pathologic features. Chest 1990;97(5):1032-6.
97. Martin RW, Duffy J, Engel AG, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med 1990;113(2):124-34.
98. Diggle GE. The toxic oil syndrome: 20 years on. Int J Clin Pract 2001;55(6):371-5.
99. James TN, Gomez-Sanchez MA, Martinez-Tello FJ, et al. Cardiac abnormalities in the toxic oil syndrome, with comparative observations on the eosinophiliamyalgia syndrome. J Am Col Cardiol 1991;18(5):1367-79.
100. Lai RS, Chiang AA, Wu M-T, et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan. Lancet 1996;348:83-5.
101. Higenbottam TW. Bronchiolitis obliterans following the ingestion of an Asian shrub leaf. Thorax 1997;52:S68-72.